Maintenance therapy for AML: are we there yet?
- PMID: 30923105
- DOI: 10.1182/blood-2019-02-897579
Maintenance therapy for AML: are we there yet?
Conflict of interest statement
Conflict-of-interest disclosure: The author is a medical advisor and receives honoraria and research funding from Celgene.
Comment on
-
Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.Blood. 2019 Mar 28;133(13):1457-1464. doi: 10.1182/blood-2018-10-879866. Epub 2019 Jan 10. Blood. 2019. PMID: 30630862 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical

